Insights

Around The World in HTAs: India – Let All Be Healthy

29 June 2023

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Shalu Jain and Gayathri Kumar take us to India.

New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 - Defining Objectives

New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives

25 May 2023

The EU Commission has set out important but controversial proposals for an AMR pull incentive for new antibiotics. In the first of this insight series, we set out seven objectives an EU fit-for-purpose pull incentive should work to achieve.

The US Inflation Reduction Act: What Do the Experts Think?

25 May 2023

In August 2022, President Biden signed the Inflation Reduction Act (IRA) into law. In this OHE Insight, Amanda Cole explores the expert discussions had at ISPOR US 2023.

Around The World in HTAs: The Netherlands – 5 Routes for New Tech

24 May 2023

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Iris Boot, Bert Vriijhoef and Lotte Steuten take us to the Netherlands.

Setting the Right Discount Rate for HTA in the Slovak Republic

21 May 2023

Health interventions such as new medicines produce costs and health-related effects not only in the year they are introduced but in all future years until they…

What is the future of health economics?

1 May 2023

There has never been a more exciting time to be a health economist. The future of health economics is about improving upon what we have and expanding the bounds of what is possible.

OHE’s contribution to health economics

1 May 2023

‘Health economists often credit the UK with being the natural home for the discipline – why?’ We conducted interviews with 18 esteemed health economists to explore…

How Restrictive are NICE ‘Optimised’ Decisions?

27 April 2023

NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.

Around The World in HTAs: Italy – What’s Next?

20 April 2023

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Claudio Jommi, Università del Piemonte Orientale Novara, and Martina Garau, OHE, take us to Italy.